

## **Therapeutic versus preventative use of Ginkgo Biloba Extract (EGb 761) against indomethacin-induced gastric ulcer in mice.**

**Ahmed M. Abd-Eldayem<sup>1</sup>, Sulaiman Mohammed Alnasser<sup>2</sup>, Hanan H. Abd-Elhafeez<sup>3</sup>, Soha A. Soliman<sup>4</sup>, Rania A. Abdel-Emam<sup>1</sup>.**

<sup>1</sup> Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, 71526, Egypt.


<sup>2</sup> Department of pharmacology and toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia.

<sup>3</sup> Department of Cell and Tissue, Faculty of Veterinary Medicine, Assiut University, Assiut, 71526, Egypt.

<sup>4</sup> Department of Histology, Faculty of Veterinary Medicine, South Valley University, Qena, 83523, Egypt.


### **Correspondence**

**Sulaiman Mohammed Alnasser:** Department of pharmacology and toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia. Postal Code: 51911, tel: 00966541841155, Email: [sm.alnasser@qu.edu.sa](mailto:sm.alnasser@qu.edu.sa)




**Figure S1.** The negative image of the effect of indomethacin or EGb 761 on COX-2 expression in gastric mucosa. (A-D): Control mice, (E-H): Indomethacin-induced ulcer (IND), (I-L): EGb 761 pre-treatment (EGb 761+IND), (M-P): EGb 761 treatment after indomethacin (IND+EGb-761). Negative marker control is shown in the inset of figure A. IND: indomethacin, EGb 761: Standardized Ginkgo biloba extract, COX-2: Cyclooxygenase-2.






**Figure S2.** The negative image of the effect of indomethacin and EGb 761 on the expression of gastric IL-1 $\beta$ . (A-D): Control mice, (E-H): Indomethacin-induced ulcer (IND), (I-L): EGb 761 pre-treatment (EGb 761+IND), (M-P): EGb 761 treatment after indomethacin (IND+EGb 761). Negative marker control is shown in the inset of figure M. IND: Indomethacin, EGb 761: Standardized Gingko biloba extract, IL-1 $\beta$ : Interleukin-1 $\beta$ .






**Figure S3.** The negative image of the effect of indomethacin and EGb 761 on the expression of gastric IL-6. (A-D): Control mice, (E-H): Indomethacin-induced ulcer (IND), (I-L): EGb 761 pre-treatment (EGb 761+IND), (M-P): EGb 761 treatment after indomethacin (IND+EGb 761). Negative marker control is shown in the inset of figure M. IND: Indomethacin, EGb 761: Standardized Ginkgo biloba extract, IL-6: Interleukin-6.





**Figure S4.** The negative image of changes in the gastric expression of TNF- $\alpha$  during indomethacin and EGb 761 administration. (A): Control mice. (B): Indomethacin-induced ulcer (IND). (C): EGb 761 pre-treatment (EGb 761+IND). (M-P): EGb 761 treatment after indomethacin (IND+EGb 761). Negative marker control is shown in the inset of figure A. IND: Indomethacin, EGb 761: Standardized Ginkgo biloba extract, TNF- $\alpha$ : Tumor necrosis factor-alpha.



**Figure S5.** Negative image of the effect of indomethacin and EGb 761 on the expression of PCNA in the gastric mucosa. (A-B): Control mice. (C-D): Indomethacin-induced ulcer. (E-F): EGb 761 pre-treatment (EGb 761+IND). (G-H): EGb 761 administration after indomethacin (IND+EGb 761). Negative marker control is shown in the inset of figure G. IND: Indomethacin, EGb 761: Standardized Gingko biloba extract, PCNA: Proliferating Cell Nuclear Antigen.